title: The effect of quercetin-3-O-β-D-glucuronopyranoside on indomethacin-induced gastric damage in rats via induction of mucus secretion and down-regulation of ICAM-1 expression.
abstract: The mechanism of the protective effect of quercetin-3-O-β-D-glucuronopyranoside (QGC) from the leaves of Rumex aqauticus on indomethacin (IND, a representative NSAID)-induced gastric damage in rats was investigated. Pre-treatment with QGC significantly attenuated IND-induced gastric mucosal injury. An increase in myeloperoxidase (MPO) activity and expression of intercellular adhesion molecule (ICAM)-1 protein and mRNA expression of the pro-inflammatory cytokines tumor necrosis factor-α and interleukin-1β, as well as a decrease in gastric mucus secretion were detected in the gastric mucosa of IND-treated rats. QGC reversed the side effect of IND on MPO activity and mucus production. Furthermore, QGC pre-treatment notably decreased ICAM-1 protein and mRNA expression of the pro-inflammatory cytokines, suggesting that QGC protection from IND-induced damage is associated with increased gastric mucus secretion, inhibition of free radical production by activated neutrophils via ICAM-1, and pro-inflammatory cytokine downregulation.
authors: College of Pharmacy, Chung-Ang University, Seoul 156-756, Korea.
authors: Xiang Mei
authors: XM
authors: Yan
authors: Min Jae
authors: MJ
authors: Joo
authors: Jae Chun
authors: JC
authors: Lim
authors: Wan Kyun
authors: WK
authors: Whang
authors: Sang Soo
authors: SS
authors: Sim
authors: Chaeuk
authors: C
authors: Im
authors: Hak Rim
authors: HR
authors: Kim
authors: Seok Yong
authors: SY
authors: Lee
authors: In Kyeom
authors: IK
authors: Kim
authors: Uy Dong
authors: UD
authors: Sohn
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D015153:Blotting, Western; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D005756:Gastritis / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D007213:Indomethacin / Q000009:adverse effects*; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis*; D053583:Interleukin-1beta / Q000096:biosynthesis; D008297:Male; D009093:Mucus / Q000378:metabolism*; D009195:Peroxidase / Q000378:metabolism; D018515:Plant Leaves / Q000737:chemistry; D011794:Quercetin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000302:isolation & purification / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D031804:Rumex / Q000737:chemistry*; D013276:Stomach Ulcer / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000897:Anti-Ulcer Agents; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; C443401:quercetin 3-O-glucuronide; D018799:Intercellular Adhesion Molecule-1; D011794:Quercetin; D009195:Peroxidase; D007213:Indomethacin